Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H22N2S.ClH |
| Molecular Weight | 346.917 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCCC(CN2C3=CC=CC=C3SC4=CC=CC=C24)C1
InChI
InChIKey=RLCFKYRNUBRPIK-UHFFFAOYSA-N
InChI=1S/C19H22N2S.ClH/c1-20-12-6-7-15(13-20)14-21-16-8-2-4-10-18(16)22-19-11-5-3-9-17(19)21;/h2-5,8-11,15H,6-7,12-14H2,1H3;1H
CNS Activity
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
75 mg 3 times / day multiple, oral Recommended Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, 20-59 |
Disc. AE: Agranulocytosis... AEs leading to discontinuation/dose reduction: Agranulocytosis (3%) Sources: |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 35 |
Disc. AE: Agranulocytosis... AEs leading to discontinuation/dose reduction: Agranulocytosis Sources: |
300 mg multiple, oral Recommended |
unhealthy, 37.1±1.5 Health Status: unhealthy Age Group: 37.1±1.5 Sex: M+F Sources: |
Disc. AE: Cycloplegia... AEs leading to discontinuation/dose reduction: Cycloplegia (4%) Sources: |
900 mg multiple, oral Highest studied dose |
unhealthy |
|
25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Sources: |
unhealthy |
Disc. AE: Jaundice... AEs leading to discontinuation/dose reduction: Jaundice Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Agranulocytosis | 3% Disc. AE |
75 mg 3 times / day multiple, oral Recommended Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: |
unhealthy, 20-59 |
| Agranulocytosis | Disc. AE | 50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 35 |
| Cycloplegia | 4% Disc. AE |
300 mg multiple, oral Recommended |
unhealthy, 37.1±1.5 Health Status: unhealthy Age Group: 37.1±1.5 Sex: M+F Sources: |
| Jaundice | Disc. AE | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Sources: |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. | 2010-03-03 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66883
Created by
admin on Mon Mar 31 17:54:36 GMT 2025 , Edited by admin on Mon Mar 31 17:54:36 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
221-020-8
Created by
admin on Mon Mar 31 17:54:36 GMT 2025 , Edited by admin on Mon Mar 31 17:54:36 GMT 2025
|
PRIMARY | |||
|
C76053
Created by
admin on Mon Mar 31 17:54:36 GMT 2025 , Edited by admin on Mon Mar 31 17:54:36 GMT 2025
|
PRIMARY | |||
|
102907
Created by
admin on Mon Mar 31 17:54:36 GMT 2025 , Edited by admin on Mon Mar 31 17:54:36 GMT 2025
|
PRIMARY | |||
|
64076
Created by
admin on Mon Mar 31 17:54:36 GMT 2025 , Edited by admin on Mon Mar 31 17:54:36 GMT 2025
|
PRIMARY | |||
|
TIW15Q5R21
Created by
admin on Mon Mar 31 17:54:36 GMT 2025 , Edited by admin on Mon Mar 31 17:54:36 GMT 2025
|
PRIMARY | |||
|
DTXSID201350400
Created by
admin on Mon Mar 31 17:54:36 GMT 2025 , Edited by admin on Mon Mar 31 17:54:36 GMT 2025
|
PRIMARY | |||
|
2975-36-2
Created by
admin on Mon Mar 31 17:54:36 GMT 2025 , Edited by admin on Mon Mar 31 17:54:36 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD